Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
205.3M
Cash
7.959M
Avg Qtr Burn
-8.696M
Short % of Float
33.27%
Insider Ownership
1.45%
Institutional Own.
68.49%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OKI-219 +/- Fulvestrant or Trastuzumab Details Breast cancer, Cancer | Phase 1 Data readout | |
Failed Discontinued | ||
Mavodelpar (REN001) Details primary mitochondrial myopathies | Failed Discontinued | |
Mavodelpar (REN001) Details long-chain fatty acid oxidation disorders | Failed Discontinued |